The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk

Therapies Aimed at Immune Cell Progenitors May Be Key to Reducing Post Myocardial Infarction Risk

November 9, 2012 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Researchers have identified hematopoietic stem and progenitor cells (HSPCs) that are liberated from bone marrow niches by a myocardial infarction (MI). These progenitor cells migrate from the bone marrow and seed the spleen. From there they provide a sustained boost in monocyte production that can contribute to artherogenesis. These cells and the process behind their release represent a novel therapeutic opportunity for survivors of MI.

You Might Also Like
  • Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
  • Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies
  • Sensory Nerves May Be Key for Osteoporosis
Also By This Author
  • Infiltrating the Disc: Mast Cells & Back Pain

“We have a good explanation why reinfarction is frequent: MI accelerates atherosclerosis,” explains Matthias Nahrendorf, MD, PhD. Dr. Nahrendorf is assistant professor at Harvard Medical School, Boston, and one of the corresponding authors of a related study published in Nature.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

MI and stroke are triggered by the destabilization and rupture of lipid-rich plaques in the arterial wall. Patients who survive acute coronary syndromes go on to have a higher risk for recurrent events. The biological connection between the first event and recurrent events was previously unknown. Dr. Nahrendorf and colleagues demonstrate that acute MI or stroke increases arthrosclerosis as well as inflammation in distal atherosclerotic plaques.

The study utilized Apoe-/- mice that develop spontaneous atherosclerotic lesions. The researchers imaged protease activity in these mice and used the activity as a marker of plaque lesion vulnerability. They found that after MI or stroke, Apoe-/- mice developed larger atherosclerotic lesions that persisted over many weeks and contained a large number of monocytes. They then searched for the source of the surplus monocytes in the plaques.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

When they measured monocyte progenitor content in mice after MI, they found an increase in the spleen. When mice were splenectomized at the time of MI, there was no acceleration in atherosclerosis.

A Puzzling Finding

The researchers were puzzled, however, because granulocyte macrophage progenitors and macrophage dendritic cell progenitors have only a limited capacity for self-renewal. This limitation was not consistent with the large numbers of monocytes that were exiting the spleen and entering the plaques. Upon further investigation, they discovered that the monocyte progenitor cells did not originate in the spleen, but rather resulted from a burst in inflammatory cells in the bone marrow.

As Dr. Nahrendorf explains, “Atherosclerosis is an inflammatory disease starting in the bone marrow. This, in addition to the spleen, is where macrophages are made.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

It appears that the sympathetic nervous system liberates the hematopoietic cells from their niches by signaling through the β3-adrenoceptor. Indeed, treatment with a β3-adrenoceptor blocker in wild-type mice reduced splenic accumulation of progenitors after MI. Treatment of Apoe-/- mice with a β3-blocker lowered protease activity, myeloid cell count, and mRNA levels of inflammatory cytokines in the plaque.

When fluorescent membrane dye-labeled HSPCs were adoptively transferred into a host, they settled in the bone marrow before the MI, and 52% migrated from the bone marrow post MI. The process appeared to be stem cell factor (SCF)–dependent because neutralization of SCF inhibited proliferation of host HSPCs as well as splenic retention of adoptively transferred HSPCs.

Although most scientists agree that atherosclerosis can be described as chronic inflammatory in nature, there is not yet an antiinflammatory therapy that is specific for atherosclerosis. “In my eyes, this opens up a new line of research and new therapeutic opportunities. In any inflammatory disease, including rheumatoid arthritis and atherosclerosis, we have to take the production of immune cells into account,” says Dr. Nahrendorf.


Dr. Pullen is a medical writer based in the Chicago area.

Reference

1. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325-329.

 

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Research Reviews Tagged With: atherosclerosis, Myocardial infarction

You Might Also Like:
  • Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
  • Key Findings in Basic Science This Year Hold Promise for Potential Rheumatology Therapies
  • Sensory Nerves May Be Key for Osteoporosis
  • Insight into Crosstalk Between Bone & Immune Systems

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.